TABLE 2.
Fasting lipids and lipoproteins
| Controls (n = 80) | Cases (n = 84) | P | |
|---|---|---|---|
| Total C (mg/dl) | 188 ± 36 | 198 ± 400 | n.s. |
| TG (mg/dl) | 147 (113–207) | 143 (104–225) | n.s. |
| VLDL TG (mg/dl) | 89 (60–151) | 91 (55–159) | n.s. |
| HDL-C (mg/dl) | 35 ± 100 | 32 ± 9 | n.s. |
| LDL-C (mg/dl) | 119 ± 34 | 127 ± 34 | n.s. |
| ApoA1 (mg/dl) | 124 ± 19 | 120 ± 22 | n.s. |
| ApoB (mg/dl) | 108 ± 27 | 117 ± 27 | 0.04 |
| ApoB48 (mg/l) | 7.6 ± 5 | 9.0 ± 7 | n.s. |
Values for total C, HDL-C, LDL-C, ApoA1, ApoB, and ApoB48 are expressed as mean ± SD. Values for TG and VLDL TG are expressed as median and interquartile range. These measurements were obtained on the day of the PP test, one month after discontinuation of any lipid-altering medications. n.s, nonsignificant.